Metabolomics study of the association between pancreatic cancer and diabetes mellitus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F19%3A43919038" target="_blank" >RIV/60461373:22340/19:43919038 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Metabolomics study of the association between pancreatic cancer and diabetes mellitus

Popis výsledku v původním jazyce

Pancreatic cancer (PC) belongs to five most lethal cancer types, with a globally reported incidence increase. Local symptoms, such as pain, jaundice, cachexia or cholangitis, appear late. Early symptomatology, including weakness, nausea, abdominal pain or weight loss, is not specific and may have many other causes. Thus, there is currently no reliable early-stage diagnosis. Moreover, the prognosis is highly unfavourable with a 5-year survival rate of only 3 to 5%. Therefore, the search for early symptoms and specific biomarkers of PC remains a subject of intense research. A proper biomarker would open the possibility to propose a screening program for PC with the aim of the positive diagnosis before local, late symptoms occur. At least 3 groups of patients can benefit from such screening program for the early diagnosis of PC, namely patients with hereditary factors, specific risk factors and pancreatogenic type 3 diabetes (T3cDM). These patients can exhibit early PC symptoms 2–3 years before any local symptoms occur, which represents a large diagnostic window. In our study, 1H NMR metabolomics was employed to plasma samples of pancreatic cancer patients, individuals with long-term diabetes mellitus type 2 (lasting more than 5 years) and healthy controls. The aim was to find  differences between these groups and to define a potential biomarker panel. Subsequently, plasma samples of the risk group, specifically patients with newly diagnosed diabetes mellitus with a duration of &lt;3 years (possible T3cDM), were analysed and the possibility of PC development was predicted. The analyses were followed by establishing a statistical model (principal component analysis, discriminant analysis). The statistical evaluation of metabolomics-based profiles provided high values of sensitivity and specificity. Thus, the achieved results showed strong potential of 1H NMR metabolomics to establish a biomarker panel that would facilitate the early diagnosis of PC and to possibility identify diabetic individuals, who are at risk of developing PC.

Název v anglickém jazyce

Metabolomics study of the association between pancreatic cancer and diabetes mellitus

Popis výsledku anglicky

Pancreatic cancer (PC) belongs to five most lethal cancer types, with a globally reported incidence increase. Local symptoms, such as pain, jaundice, cachexia or cholangitis, appear late. Early symptomatology, including weakness, nausea, abdominal pain or weight loss, is not specific and may have many other causes. Thus, there is currently no reliable early-stage diagnosis. Moreover, the prognosis is highly unfavourable with a 5-year survival rate of only 3 to 5%. Therefore, the search for early symptoms and specific biomarkers of PC remains a subject of intense research. A proper biomarker would open the possibility to propose a screening program for PC with the aim of the positive diagnosis before local, late symptoms occur. At least 3 groups of patients can benefit from such screening program for the early diagnosis of PC, namely patients with hereditary factors, specific risk factors and pancreatogenic type 3 diabetes (T3cDM). These patients can exhibit early PC symptoms 2–3 years before any local symptoms occur, which represents a large diagnostic window. In our study, 1H NMR metabolomics was employed to plasma samples of pancreatic cancer patients, individuals with long-term diabetes mellitus type 2 (lasting more than 5 years) and healthy controls. The aim was to find  differences between these groups and to define a potential biomarker panel. Subsequently, plasma samples of the risk group, specifically patients with newly diagnosed diabetes mellitus with a duration of &lt;3 years (possible T3cDM), were analysed and the possibility of PC development was predicted. The analyses were followed by establishing a statistical model (principal component analysis, discriminant analysis). The statistical evaluation of metabolomics-based profiles provided high values of sensitivity and specificity. Thus, the achieved results showed strong potential of 1H NMR metabolomics to establish a biomarker panel that would facilitate the early diagnosis of PC and to possibility identify diabetic individuals, who are at risk of developing PC.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10406 - Analytical chemistry

Projekt

<a href="/cs/project/NV16-31028A" target="_blank" >NV16-31028A: Účinnost nových spektroskopických biomarkerů pro detekci časného stádia karcinomu pankreatu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů